ABBV · News · 20260910N

Acquisition / Partnership / Divestiture

AbbVie Inc. · 2026-09-10 · Importance 58 · Surprise 42

AbbVie’s collaboration with ADARx Pharmaceuticals provided ADARx with $335 million in upfront cash. The agreement includes $385 million in option payments and up to $7.45 billion in milestone payments, plus royalties. ADARx is developing Onvuzosiran for hereditary angioedema, with Phase 3 topline data expected by the end of 2027 and a potential NDA filing in 2028.

Key facts

• Firestone Capital Management lowered its holdings in AbbVie Inc. by 75.5% during the undefined quarter and owned 973 shares after selling 2,996 shares during the period. source
• B. Metzler seel. Sohn and Co. AG lessened its stake in AbbVie Inc. by 8.7% in the second quarter and owned 867,621 shares after selling 82,764 shares during the period. source
• Alley Investment Management Company LLC decreased its stake in AbbVie Inc. by 4.2% during the second quarter and owned 107,568 shares after selling 4,711 shares during the period. source
• AXQ Capital LP purchased a new stake in AbbVie Inc. during the second quarter of 2,437 shares valued at approximately $613,000. source